Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02118714 · ClinicalTrials.gov registry record · Phase 2
Atrasentan Spermatogenesis and Testicular Function
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02118714 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 20 participants.
The verdict
NCT02118714, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the effects of Atrasentan on sperm production and testicular function in male subjects with Type 1 or 2 Diabetes and Nephropathy. This study included 2 periods: a Treatment Period (up to 26 weeks) followed by an Observational Period (up to an additional 52 weeks).
Interventions
- DRUG Atrasentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-04-06 |
| Est. Completion | 2018-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02118714
The ClinicalTrials.gov registry entry for NCT02118714 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atrasentan is the first listed.
NCT02118714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02118714 about?
NCT02118714 is a clinical study titled "Atrasentan Spermatogenesis and Testicular Function". This study is being conducted to evaluate the effects of Atrasentan on sperm production and testicular function in male subjects with Type 1 or 2 Diabetes and Nephropathy. This study included 2 periods: a Treatment Period (up to 26 weeks) followed by an Observational Period (up to an additional 52 ...
What is the current status of trial NCT02118714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-04-06. Estimated completion is 2018-07-16.
What interventions are being tested in trial NCT02118714?
The interventions under investigation include: Atrasentan (DRUG).
Who is sponsoring clinical trial NCT02118714?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.